11/20/2023 0 Comments Silverback therapeutics news![]() We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. This article by Simply Wall St is general in nature. Alternatively, email editorial-team (at). Have feedback on this article? Concerned about the content? Get in touch with us directly. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts) Of course, you might find a fantastic investment by looking elsewhere. On another note, Silverback Therapeutics has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about. We don't think its cash burn is particularly problematic, but after considering the range of factors in this article, we do think shareholders should be monitoring how it changes over time. Is Silverback Therapeutics' Cash Burn A Worry?Įven though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Silverback Therapeutics' cash runway was relatively promising. That's very high expenditure relative to the company's size, suggesting it is an extremely high risk stock. Silverback Therapeutics has a market capitalisation of US$106m and burnt through US$68m last year, which is 64% of the company's market value. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Commonly, a business will sell new shares in itself to raise cash and drive growth. Companies can raise capital through either debt or equity. Given its cash burn trajectory, Silverback Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Story continues Can Silverback Therapeutics Raise More Cash Easily? Depicted below, you can see how its cash holdings have changed over time. There's no doubt that this is a reassuringly long runway. That means it had a cash runway of about 3.7 years as of December 2021. Looking at the last year, the company burnt through US$68m. When Silverback Therapeutics last reported its balance sheet in December 2021, it had zero debt and cash worth US$254m. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.Ĭheck out our latest analysis for Silverback Therapeutics Does Silverback Therapeutics Have A Long Cash Runway? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. So, the natural question for Silverback Therapeutics ( NASDAQ:SBTX) shareholders is whether they should be concerned by its rate of cash burn. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Subscribe to Morningstar Investor today.There's no doubt that money can be made by owning shares of unprofitable businesses. Write to Sabela Ojea at Dow Jones NewswiresĬopyright (c) 2022 Dow Jones & Company, Inc.Įvaluate the market like an analyst. ![]() who experience this type of allergic reactions, the company said. There are between 25 million to 40 million people in the U.S. Type 1 emergency allergic reactions are potentially life-threatening events that can occur within minutes after being exposed to an allergen that need further treatment options, Silverback Therapeutics said. The only FDA-approved medication for these reactions are epinephrine autoinjectors, but some patients delay this emergency because of being afraid of needles, amid other reasons, the company said. Neffy has the potential to become the first needle-free medicine to treat allergic reaction, Silverback Therapeutics said. The FDA has assigned a prescription drug user fee act target action date that is expected in mid-2023, Silverback Therapeutics said. The clinical-stage biopharmaceutical company said Neffy was developed by ARS Pharmaceuticals Inc., the company it acquired in July for the potential commercialization of the treatment. Food and Drug Administration has accepted for review its new drug application for Neffy, an emergency nasal spray to treat allergic reactions.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |